Novopharm Ranitidine Advantage May Be "Insurmountable," Torpharm Argues
This article was originally published in The Tan Sheet
Executive Summary
Apotex/Torpharm says the market advantage provided to competitor Novopharm by an award of 180-day market exclusivity for private label OTC ranitidine 75 mg may have long-term adverse effects on competing generic firms. The Apotex division filed a petition March 12 for a preliminary injunction against Novopharm in Chicago federal court.